

RESEARCH MONOGRAPH . COMPOUND PROFILE

Cariprazine

A D3-preferring dopamine receptor partial agonist developed by Gedeon Richter as an atypical antipsychotic, distinguished from aripiprazole and brexpiprazole by subnanomolar D3 affinity exceeding that of endogenous dopamine and by the generation of two pharmacologically active long-lived metabolites that collectively produce an effective half-life of approximately one week.

DOCUMENT	KDC-MN-1503
ISSUED	2026-05-15
REVISION	1.0
AUTHOR	Kodi <i>ac</i> bio <i>l</i> abs Research
COMPOUND CLASS	Dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist atypical antipsychotic

ABSTRACT

Cariprazine (RGH-188; marketed as Vraylar) is a dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist approved by the United States Food and Drug Administration for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, depressive episodes associated with bipolar I disorder (bipolar depression), and adjunctive treatment of major depressive disorder in adults with inadequate response to antidepressant therapy. The compound was discovered by Gedeon Richter Plc. in Budapest, Hungary, first synthesized in 2002, and advanced through clinical development in partnership with Forest Laboratories (subsequently Actavis, Allergan, and AbbVie), receiving initial FDA approval in September 2015 and European Medicines Agency approval in 2017 under the trade name Reagila. Cariprazine is pharmacologically distinguished from the other clinically marketed dopamine partial agonist antipsychotics (aripiprazole, brexpiprazole) by its exceptionally high affinity for the dopamine D3 receptor (K_i approximately 0.085 nM), which exceeds the affinity of endogenous dopamine for the same receptor and produces a degree of D3 occupancy at clinical doses that is not achievable by any other marketed antipsychotic. The D3-preferring profile, with approximately 6- to 8-fold selectivity over D2, is hypothesized to underwrite the compound's differentiated efficacy on negative symptoms of schizophrenia, cognitive impairment, anhedonia, and motivational deficits, domains that are poorly served by D2-predominant antipsychotic pharmacology. Cariprazine additionally binds the serotonin 5-HT1A receptor as a partial agonist (K_i approximately 2.6 nM) and

the serotonin 5-HT_{2B} receptor with high affinity (K_i approximately 0.6 nM), while showing low affinity for histamine H₁, muscarinic, and alpha-1 adrenergic receptors, a selectivity profile that predicts low sedation, low anticholinergic burden, and low orthostatic hypotension relative to the broader atypical antipsychotic class.

The pharmacokinetic profile of cariprazine is dominated by its two major active metabolites, desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR), both of which possess pharmacological activity comparable to the parent compound at D₃, D₂, and 5-HT_{1A} receptors. The parent compound has a half-life of 2 to 4 days; DCAR has a half-life of 1 to 2 days; and DDCAR, the predominant circulating active species at steady state, has a half-life of 1 to 3 weeks. The effective half-life of total active moieties is approximately 1 week, with steady-state equilibrium achieved at approximately 3 weeks of daily dosing. This pharmacokinetic profile has important implications for dose titration (clinical effects may lag dose changes by days to weeks), for drug-drug interactions (strong CYP3A4 inhibitors require dose reduction; strong CYP3A4 inducers are contraindicated), and for washout after discontinuation (pharmacological activity persists for several weeks).

The clinical evidence base comprises multiple Phase 2 and Phase 3 randomized controlled trials across four approved indications, a head-to-head Phase 3b trial against risperidone for predominant negative symptoms of schizophrenia (demonstrating statistically significant superiority on the PANSS factor score for negative symptoms), and relapse prevention data in schizophrenia. The adverse-event profile is characterized by akathisia and extrapyramidal symptoms as the most common treatment-

emergent adverse events (dose-dependent, typically mild to moderate), with a comparatively favorable metabolic profile (minimal weight gain, negligible effects on glucose and lipid parameters) and low prolactin elevation relative to other atypical antipsychotics. This monograph reviews the chemistry, receptor pharmacology, pharmacokinetics, preclinical pharmacology, clinical evidence across all approved and investigational indications, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five alternative atypical antipsychotic agents against cariprazine on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Cariprazine.

Marketed names: Vraylar (AbbVie; United States), Reagila (Gedeon Richter; European Union member states, United Kingdom, and other jurisdictions).

Development codes: RGH-188 (Gedeon Richter). The development code is the canonical identifier in the early pharmacology and Phase 1 literature and the primary identifier under which the initial receptor binding characterization and pre-clinical behavioral pharmacology were published [1, 2].

Chemical Abstracts Service registry numbers: 839712-12-8 (free base), 1083076-69-0 (hydrochloride salt). The free base is the synthetic form; the hydrochloride salt is the formulated material in the marketed capsule dosage form.

International Union of Pure and Applied Chemistry name: trans-N-(1-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}cyclohexyl)-N',N'-dimethylurea. The compound is a dichlorophenylpiperazine derivative linked through an ethylene spacer to a trans-4-aminocyclohexyl group bearing an N',N'-dimethylurea substituent.

1.2 Structural class and chemistry

Cariprazine belongs to the piperazine-cyclohexyl urea structural class within the broader arylpiperazine family of dopamine receptor ligands. The structural class places it in a chemical series distinct from the phenylindole (sertindole), benzisoxazole (risperidone, paliperidone), thienobenzodiazepine (olanzapine), dibenzodiazepine (clozapine), and quinolinone (aripiprazole, brexpiprazole) scaffolds of other atypical antipsychotics [3].

Molecular formula: C₂₁H₃₂Cl₂N₄O (free base); C₂₁H₃₃Cl₃N₄O (hydrochloride salt).

Exact mass: 426.1948 g/mol (free base, monoisotopic).

Molecular weight: 427.41 g/mol (free base); 463.87 g/mol (hydrochloride salt).

Physical properties: White to off-white crystalline powder. The hydrochloride salt is soluble in water at acidic pH; the free base has limited aqueous solubility. The compound is soluble in dimethyl sulfoxide, methanol, and other polar organic solvents. The melting point of the hydrochloride salt is reported at approximately 205 to 210 degrees Celsius.

Stereochemistry: Cariprazine contains two stereocenters at carbons 1 and 4 of the cyclohexane ring and is supplied as the trans-(1r,4r) diastereomer. The trans configuration places the ethylpiperazine chain and the dimethylurea substituent in equatorial positions on the cyclohexane chair, which is the thermodynamically favored and pharmacologically active configuration. The cis diastereomer has not been advanced as a clinical candidate. Investigators acquiring research-grade cariprazine should confirm diastereomeric purity by chiral high-performance liquid chromatography or nuclear magnetic resonance spectroscopy.

1.3 Synthesis

The published synthesis of cariprazine proceeds through convergent assembly of two principal fragments: the 1-(2,3-dichlorophenyl)piperazine moiety and the trans-4-aminocyclohexyl-N,N-dimethylurea moiety, joined through an ethylene bridge [3]. The piperazine fragment is commercially available or prepared by standard Buchwald-Hartwig coupling or nucleophilic aromatic substitution of 1,2,3-trichlorobenzene with piperazine. The cyclohexyl urea fragment is prepared from trans-4-aminocyclohexanol or trans-1,4-diaminocyclohexane by selective urea formation with dimethylcarbamoyl chloride or by reaction with dimethylamine and a carbonyl equivalent. The two fragments are joined by N-alkylation of the piperazine nitrogen with a 2-haloethyl derivative of the cyclohexyl urea, or alternatively through reductive amination. The product is purified by column chromatography or recrystallization and characterized by nuclear magnetic resonance spectroscopy, mass spectrometry, and high-performance liquid chromatography. The hydrochloride salt is formed by addition of stoichiometric hydrochloric acid in a suitable solvent system. Industrial synthesis at Gedeon Richter has been optimized for trans-diastereomeric purity (greater than 99.5 percent) and for control of dichlorophenylpiperazine regiochemistry [4].

2. Abstract

Cariprazine (RGH-188; Vraylar, Reagila) is a dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist that occupies a unique pharmacological position among marketed antipsychotics by virtue of its subnanomolar affinity for the D3 receptor (K_i approximately 0.085 nM), which exceeds the affinity of endogenous dopamine itself for this receptor subtype [1, 2]. This D3-preferring profile, combined with partial agonist activity at D2 and 5-HT1A receptors and low affinity for histaminergic, muscarinic, and alpha-1 adrenergic sites, produces a clinical pharmacology that is differentiated from both the D2-predominant atypical antipsychotics (risperidone, olanzapine, quetiapine) and the other dopamine partial agonists (aripiprazole, brexpiprazole) on dimensions of negative symptom efficacy, cognitive function, metabolic safety, and prolactin elevation [5, 6].

The compound was discovered by medicinal chemists at Gedeon Richter Plc. in Budapest, Hungary, first synthesized in 2002, and entered clinical trials in 2004 under a collaborative development agreement with Forest Laboratories (later Actavis, Allergan, and AbbVie) [4]. The FDA granted initial approval in September 2015 for schizophrenia and bipolar I mania in adults, followed by approval for bipolar I depression in May 2019, and for adjunctive treatment of major depressive disorder in December 2022. The European Medicines Agency approved cariprazine (Reagila) in July 2017 for schizophrenia. Pediatric approvals followed, with FDA approval for bipolar I mania in patients aged 10 years and older and for schizophrenia in patients aged 13 years and older.

The pharmacokinetic signature of cariprazine is exceptional among antipsychotics. The parent compound undergoes sequential CYP3A4-mediated demethylation to produce two active metabolites: desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR). Both metabolites retain pharmacological activity comparable to the parent at D3, D2, and 5-HT1A receptors [7]. The half-life progression from parent (2 to 4 days) through DCAR (1 to 2 days) to DDCAR (1 to 3 weeks) produces an effective half-life of the total active moiety pool of approximately 1 week, with steady-state equilibrium reached at approximately 3 weeks [8].

This ultra-long functional half-life has both advantages (forgiving of missed doses, smooth plasma levels, sustained receptor occupancy) and disadvantages (slow onset of full effect, prolonged washout, delayed emergence of some adverse events).

The clinical evidence base is robust across four approved indications. Three short-term Phase 3 trials in acute schizophrenia demonstrated efficacy at doses of 1.5 to 9 mg/day [9, 10, 11]. A relapse prevention trial demonstrated superiority over placebo in time to relapse [12]. A Phase 3b head-to-head trial against risperidone in patients with predominant negative symptoms of schizophrenia demonstrated statistically significant superiority of cariprazine on the PANSS factor score for negative symptoms, a result that is unique among antipsychotics and has positioned cariprazine as the preferred agent for negative-symptom-predominant schizophrenia [13]. Three Phase 3 trials in bipolar I mania demonstrated efficacy at 3 to 12 mg/day [14]. Three Phase 3 trials in bipolar I depression demonstrated efficacy at 1.5 to 3 mg/day on the Montgomery-Asberg Depression Rating Scale (MADRS) [15, 16]. Two Phase 3 trials of adjunctive cariprazine in major depressive disorder with inadequate response to antidepressants supported the MDD indication at 1.5 mg/day [17, 18].

The adverse-event profile is dominated by akathisia and extrapyramidal symptoms, which are dose-dependent, typically mild to moderate in severity, and manageable with dose adjustment or short-term benzodiazepine or beta-blocker therapy. The metabolic profile is comparatively favorable: mean weight gain in short-term trials is approximately 1 kg, and clinically significant changes in fasting glucose, total cholesterol, and triglycerides are infrequent [19]. Prolactin elevation is minimal. The compound carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis and for suicidal thoughts and behaviors in young adults, consistent with the class labeling for all atypical antipsychotics.

3. Discovery and Development History

3.1 Origin

Cariprazine was conceived and synthesized at Gedeon Richter Plc. (Budapest, Hungary) as part of a medicinal chemistry program targeting dopamine D3 receptor-preferring partial agonists in the late 1990s and early 2000s [4]. The D3 receptor had been identified through the work of Sokoloff, Giros, Martres, Bouthenet, and Schwartz (1990) as a dopamine receptor subtype expressed predominantly in limbic and cortical brain regions, with lower density in the dorsal striatum (the principal site of D2-mediated motor side effects), raising the hypothesis that D3-preferring compounds could produce antipsychotic efficacy with reduced extrapyramidal liability and with activity on negative, cognitive, and affective symptom domains [20]. The Gedeon Richter team systematically explored arylpiperazine scaffolds and identified the dichlorophenylpiperazine-cyclohexyl urea series as combining high D3 affinity, moderate D2 partial agonism, and 5-HT_{1A} partial agonism in a single molecule. Cariprazine (RGH-188) was selected from this series as the clinical candidate on the basis of its binding profile, functional pharmacology, oral bioavailability, and tolerability in early preclinical toxicology [1].

3.2 Partnership and clinical development

In 2004, Gedeon Richter entered a licensing and co-development agreement with Forest Laboratories, Inc. for the development and commercialization of cariprazine in the United States and Canada. Forest Laboratories contributed clinical development infrastructure and U.S. regulatory expertise. Forest Laboratories was acquired by Actavis in 2014, Actavis merged with Allergan in 2015, and Allergan was subsequently acquired by AbbVie in 2020. Throughout these corporate transitions, the development partnership with Gedeon Richter was maintained, and the compound advanced continuously through Phase 2 and Phase 3 clinical programs [4].

3.3 Regulatory approvals

The FDA approved cariprazine (Vraylar) on September 17, 2015 for two indications: the treatment of schizophrenia in adults and the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [21]. On May 28, 2019, the FDA approved a supplemental new drug application for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults [22]. On December 16, 2022, the FDA approved cariprazine as adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults [23]. Pediatric indications for bipolar I mania (ages 10 and older) and schizophrenia (ages 13 and older) followed.

The European Medicines Agency approved cariprazine (Reagila) in July 2017 for the treatment of schizophrenia in adults, with the schizophrenia indication being the only approved indication in the European Union. Cariprazine is also approved in additional jurisdictions globally, including Canada, Australia, and several countries in Asia and Latin America.

3.4 Significance

Cariprazine represents the first original Hungarian-developed pharmaceutical compound to reach the United States market in over a century, a milestone for the Hungarian pharmaceutical industry and for Gedeon Richter [4]. Scientifically, cariprazine is the first marketed antipsychotic for which D3 receptor preferential binding is the defining pharmacological characteristic, validating the D3 hypothesis that had been discussed in the psychiatric pharmacology literature since the early 1990s.

4. Mechanism of Action

Cariprazine is a multi-receptor ligand with a receptor binding profile that is defined by three principal activities: high-affinity partial agonism at the dopamine D3 receptor, moderate-affinity partial agonism at the dopamine D2 receptor, and partial agonism at the serotonin 5-HT_{1A} receptor. These activities, operating at the doses achieved by the approved oral formulation, produce a composite pharmacological effect that is differentiated from both the D2-predominant atypical antipsychotics and the other dopamine partial agonists.

4.1 Dopamine D3 receptor partial agonism

The dopamine D3 receptor is a member of the D2-like family of G-protein-coupled receptors (which includes D2, D3, and D4) and signals through inhibitory Gi/Go-coupled pathways to reduce adenylyl cyclase activity, modulate potassium and calcium channel conductance, and regulate beta-arrestin-mediated signaling cascades. The D3 receptor is expressed at highest density in the ventral striatum (nucleus accumbens), islands of Calleja, hippocampus, prefrontal cortex, and other limbic and cortical regions, with substantially lower expression in the dorsal striatum (caudate and putamen) relative to D2 [20].

Cariprazine binds the D3 receptor with subnanomolar affinity (K_i approximately 0.085 nM), which is the highest D3 affinity among marketed antipsychotics and exceeds the affinity of endogenous dopamine for the D3 receptor [1, 2]. The functional activity at D3 is partial agonism, with intrinsic activity of approximately 40 to 70 percent of the maximal dopamine response in heterologous expression systems, depending on the assay and cell background [2]. At clinical doses, cariprazine achieves essentially complete occupancy of D3 receptors in the brain, as demonstrated by positron emission tomography studies in non-human primates and in humans using the D3-preferring radioligand [¹¹C]-(+)-PHNO [24].

The D3 receptor occupancy is hypothesized to mediate cariprazine's effects on negative symptoms (avolition, anhedonia, alogia, blunted affect, asociality), cognitive impairment, and motivational deficits in schizophrenia. The D3 receptor modulates reward circuitry, motivation, and cognitive flexibility through its expression in the nucleus accumbens, prefrontal cortex, and hippocampus. Preclinical studies

have demonstrated that D3-preferring agents improve performance on tasks measuring cognitive flexibility, social interaction, and motivation in animal models of schizophrenia [25, 26].

4.2 Dopamine D2 receptor partial agonism

Cariprazine binds the dopamine D2 receptor with high affinity (K_i approximately 0.49 nM), approximately 6- to 8-fold lower than its D3 affinity [1, 2]. Functional activity at D2 is partial agonism with intrinsic activity of approximately 20 to 40 percent of maximal dopamine response. This partial agonist profile means that cariprazine acts as a functional antagonist in the presence of high dopamine tone (as hypothesized in the mesolimbic pathway in psychosis) and as a functional agonist in the presence of low dopamine tone (as hypothesized in the mesocortical and tuberoinfundibular pathways). The D2 partial agonism is the principal mechanism underlying the antipsychotic efficacy against positive symptoms and is the pharmacological basis shared with aripiprazole and brexpiprazole, though cariprazine's intrinsic activity at D2 is lower than that of aripiprazole and similar to that of brexpiprazole [5, 6].

PET studies in healthy volunteers and in patients with schizophrenia have demonstrated that cariprazine at therapeutic doses (1.5 to 6 mg/day) achieves D2 receptor occupancy of approximately 60 to 80 percent in the striatum, within the therapeutic window established for antipsychotic efficacy (greater than 60 percent) and below the threshold associated with high extrapyramidal symptom liability (greater than 80 percent) [24].

4.3 Serotonin 5-HT_{1A} receptor partial agonism

Cariprazine binds the serotonin 5-HT_{1A} receptor with high affinity (K_i approximately 2.6 nM) and functions as a partial agonist [1, 2]. The 5-HT_{1A} receptor is expressed on serotonergic neurons of the dorsal raphe (presynaptic autoreceptors) and on postsynaptic neurons in the hippocampus, cortex, and amygdala. Activation of presynaptic 5-HT_{1A} autoreceptors reduces serotonergic firing, while activation of postsynaptic 5-HT_{1A} receptors modulates glutamatergic and GABAergic neurotransmission. The 5-HT_{1A} partial agonist activity is hypothesized to contribute to anxiolytic and antidepressant effects and to ameliorate D2 antagonist-induced extrapyramidal symptoms through modulation of basal ganglia circuits.

4.4 Additional receptor interactions

Cariprazine shows high affinity for the serotonin 5-HT_{2B} receptor (K_i approximately 0.6 nM) as an antagonist. The clinical significance of 5-HT_{2B} antagonism is uncertain but may contribute to anxiolytic activity [2]. Affinity for the serotonin 5-HT_{2A} receptor is relatively low (K_i approximately 18.6 nM), substantially lower than the D₂ and D₃ affinities and lower than the 5-HT_{2A} affinity of risperidone, olanzapine, and quetiapine [2]. Cariprazine shows low affinity for histamine H₁ receptors (K_i greater than 1000 nM), muscarinic M₁ receptors (essentially no binding), and alpha-1A adrenergic receptors (K_i approximately 155 nM) [2]. This selectivity profile predicts low sedation (low H₁ binding), low anticholinergic burden (no muscarinic binding), and low orthostatic hypotension (low alpha-1 binding) relative to the broader atypical antipsychotic class.

4.5 Active metabolite pharmacology

The two major active metabolites, DCAR and DDCAR, retain pharmacological activity comparable to the parent compound. DCAR shows D₃ K_i approximately 0.057 nM (slightly higher affinity than the parent), D₂ K_i approximately 1.4 nM, and 5-HT_{1A} K_i approximately 1.7 nM [7]. DDCAR shows similar receptor binding affinities. Because DDCAR is the predominant circulating active species at steady state (accounting for approximately 30 to 40 percent of total active moieties), the composite pharmacological effect at steady state is a weighted average of parent, DCAR, and DDCAR activity. The receptor occupancy studies with PET confirm that the long-lived metabolites contribute to sustained D₂ and D₃ receptor occupancy for weeks after discontinuation [24].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Cariprazine is well absorbed after oral administration. Peak plasma concentrations of the parent compound are achieved approximately 3 to 6 hours post-dose [8]. Oral bioavailability is high; preclinical data in rats indicated approximately 52 percent absolute bioavailability, and the formulation optimization for the marketed capsule supports near-complete absorption in humans. Food does not produce clinically relevant effects on the rate or extent of absorption; the compound may be administered without regard to meals [28].

5.2 Distribution

Cariprazine exhibits extensive tissue distribution with a large apparent volume of distribution of approximately 20 L/kg, indicating substantial partitioning into tissues including the central nervous system [8]. Plasma protein binding is greater than 98 percent for cariprazine and its active metabolites, predominantly to albumin and alpha-1-acid glycoprotein. The compound crosses the blood-brain barrier effectively, as demonstrated by PET receptor occupancy studies showing D2 and D3 occupancy in the striatum and extrastriatal regions at therapeutic doses [24].

5.3 Metabolism

Cariprazine undergoes extensive hepatic metabolism. The principal metabolic pathway is sequential N-demethylation of the dimethylurea moiety, catalyzed primarily by CYP3A4 with minor contributions from CYP2D6 [8, 28]. The first demethylation produces DCAR (desmethyl-cariprazine); the second demethylation produces DDCAR (didesmethyl-cariprazine). DDCAR is subsequently hydroxylated by CYP3A4 to an inactive hydroxylated metabolite that is excreted.

The metabolic cascade produces a striking pharmacokinetic signature:

The parent compound (cariprazine) has a half-life of 2 to 4 days. DCAR has a half-life of 1 to 2 days. DDCAR has a half-life of 1 to 3 weeks. The median time to 90 percent of steady state is approximately 1 week for cariprazine and DCAR and approximately 3 weeks for DDCAR [8].

At steady state on chronic daily dosing, the approximate molar fractions of the three active species are: cariprazine approximately 30 percent, DCAR approximately 10 percent, and DDCAR approximately 30 to 40 percent of total active moieties. DDCAR therefore becomes the predominant circulating active species at equilibrium.

Population pharmacokinetic modeling has characterized cariprazine disposition as a three-compartment model with zero-order input followed by first-order absorption and elimination, while DCAR and DDCAR follow two-compartment models with linear elimination [29].

5.4 Elimination

The principal elimination pathway is hepatic metabolism to inactive hydroxylated metabolites that are subsequently conjugated and excreted. Renal excretion of unchanged cariprazine is minimal. After discontinuation of chronic dosing, the pharmacological activity of the total active moiety pool persists for several weeks owing to the long half-life of DDCAR. The effective functional half-life (defined as the time for 50 percent reduction in total active moiety exposure after discontinuation) is approximately 2 to 4 weeks [8].

5.5 Routes of administration

Cariprazine is marketed exclusively as an oral capsule formulation in strengths of 1.5 mg, 3 mg, 4.5 mg, and 6 mg. No parenteral, intramuscular, or long-acting injectable formulation is marketed. The oral capsule is the only route used in clinical practice and in all published clinical trials [28].

5.6 Special populations

CYP3A4 interactions: Because CYP3A4 is the principal metabolizing enzyme, strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) substantially increase cariprazine exposure. The prescribing label recommends a maximum

dose reduction to 1.5 mg daily or 3 mg every other day when co-administered with strong CYP3A4 inhibitors. Strong CYP3A4 inducers (carbamazepine, rifampin, phenytoin) reduce cariprazine exposure and are not recommended for concomitant use [28].

CYP2D6 poor metabolizers: CYP2D6 poor metabolizers show a modest (approximately 30 percent) increase in total active moiety exposure; no dose adjustment is required based on CYP2D6 status alone [28].

Renal impairment: No dose adjustment is required for mild to moderate renal impairment. Cariprazine has not been adequately studied in severe renal impairment [28].

Hepatic impairment: No dose adjustment is required for mild to moderate hepatic impairment. The compound has not been adequately studied in severe hepatic impairment [28].

Pediatric patients: Approved for bipolar I mania in patients 10 years and older and for schizophrenia in patients 13 years and older. Pharmacokinetic data in pediatric populations support the use of the same dose range as adults [28].

6. Preclinical Pharmacology

6.1 In vitro receptor pharmacology

The comprehensive receptor binding profile of cariprazine has been characterized in cloned human receptor assays [1, 2]. Key binding constants (K_i , nM): D3 = 0.085; D2L = 0.49; D2S = 0.71; 5-HT1A = 2.6; 5-HT2B = 0.58; 5-HT2A = 18.6; H1 = greater than 1000; M1 = essentially no binding; α -1A = 155. Functional assays in GTPgammaS and cAMP systems confirmed partial agonist activity at D3 (intrinsic activity approximately 40 to 70 percent), D2 (intrinsic activity approximately 20 to 40 percent), and 5-HT1A (intrinsic activity approximately 30 to 60 percent) [2].

6.2 In vivo behavioral pharmacology

In rodent models, cariprazine demonstrates antipsychotic-like activity in the amphetamine-induced hyperlocomotion, apomorphine-induced climbing, and conditioned avoidance response paradigms at doses producing estimated D2 occupancy of 60 to 80 percent [25]. Importantly, cariprazine shows a wider separation between doses producing antipsychotic-like effects and doses producing catalepsy (a measure of extrapyramidal liability) relative to haloperidol and risperidone, consistent with the D3-preferring and partial agonist profile [25, 26].

In models relevant to negative symptoms and cognition, cariprazine reverses phencyclidine-induced social interaction deficits in rats and improves novel object recognition performance at doses lower than those required for antipsychotic-like activity, suggesting that the D3-preferring mechanism contributes to procognitive and prosocial effects at sub-antipsychotic D2 occupancy [25, 26]. In models of anhedonia (sucrose preference test) and motivation (progressive ratio operant responding), cariprazine produces pro-motivational effects that are blocked by selective D3 antagonists, confirming D3 receptor mediation [26].

6.3 Metabolite pharmacology

The preclinical pharmacodynamic characterization of DCAR and DDCAR by Gyertyan et al. (2011) demonstrated that both metabolites are pharmacologically active at D3, D2, and 5-HT1A receptors with binding affinities and functional activities comparable to the parent compound [7]. In behavioral models, DCAR and DDCAR produced antipsychotic-like, procognitive, and prosocial effects at comparable doses to cariprazine. This finding established that the long-lived metabolites are not merely pharmacokinetic artifacts but are therapeutically contributing species, a critical consideration for understanding the clinical pharmacology of the compound.

7. Clinical Evidence Base

7.1 Schizophrenia: acute treatment

Three pivotal Phase 3, randomized, double-blind, placebo-controlled trials established the efficacy of cariprazine in acute exacerbation of schizophrenia.

Study RGH-MD-16 (Durgam et al. 2014): A 6-week trial in 732 patients with acute schizophrenia randomized to placebo, cariprazine 1.5 mg/day, or cariprazine 3 mg/day. Both cariprazine doses demonstrated statistically significant improvement versus placebo on the PANSS total score at week 6 (least squares mean difference: 1.5 mg = -6.8, $p = 0.0044$; 3 mg = -8.8, $p = 0.0002$) [9].

Study RGH-MD-04 (Kane et al. 2015): A 6-week trial in 617 patients randomized to placebo, cariprazine 3 to 6 mg/day, or cariprazine 6 to 9 mg/day. Both dose ranges demonstrated statistically significant improvement on PANSS total score (3-6 mg: -6.8, $p = 0.0004$; 6-9 mg: -9.9, p less than 0.0001) [10].

Study RGH-MD-05 (Durgam et al. 2015): A 6-week trial in 446 patients randomized to placebo, cariprazine 3 to 6 mg/day, or cariprazine 6 to 9 mg/day. Both dose ranges were superior to placebo on PANSS total score [11].

Across these trials, response rates (defined as 30 percent or greater reduction in PANSS total score) ranged from 31 to 43 percent for cariprazine compared to 21 to 29 percent for placebo. The approved dose range for schizophrenia is 1.5 to 6 mg/day, with a recommended starting dose of 1.5 mg/day.

7.2 Schizophrenia: relapse prevention

A Phase 3, randomized, double-blind, placebo-controlled withdrawal trial (Durgam et al. 2017) enrolled patients with schizophrenia who had been stabilized on open-label cariprazine 3 to 9 mg/day for 20 weeks, then randomized to continued cariprazine or switch to placebo [12]. The primary endpoint was time to relapse. Cariprazine significantly delayed relapse compared to placebo (hazard ratio 0.45, p less than 0.001), with relapse rates of 24.8 percent for cariprazine versus 47.5 percent for placebo at week 26 to 72 of double-blind treatment.

7.3 Schizophrenia: predominant negative symptoms

The Phase 3b trial (Nemeth et al. 2017; published in *The Lancet*) is the landmark study that differentiates cariprazine from all other antipsychotics in the negative symptom domain [13]. This 26-week, randomized, double-blind, active-controlled trial enrolled 461 adults with schizophrenia, stable illness (greater than 2 years duration), and predominant negative symptoms (greater than 6 months duration with PANSS negative subscale score of 26 or greater). Patients were randomized to fixed-dose cariprazine (target dose 4.5 mg/day, range 3 to 6 mg/day) or risperidone (target dose 4 mg/day, range 3 to 6 mg/day). The primary endpoint was change from baseline to week 26 on the PANSS factor score for negative symptoms (PANSS-FSNS).

Cariprazine demonstrated statistically significant superiority over risperidone on the primary endpoint (least squares mean change: cariprazine -8.90 versus risperidone -7.44; difference -1.46, $p = 0.0308$; effect size $d = 0.31$) [13]. Post hoc analyses demonstrated that the cariprazine advantage was evident across individual PANSS negative symptom items (N1 blunted affect, N2 emotional withdrawal, N3 poor rapport, N4 passive/apathetic social withdrawal, N6 lack of spontaneity) and across all PANSS-derived factor scores, suggesting broad-spectrum efficacy on the negative symptom construct rather than improvement limited to a single sub-domain [30].

This trial is unique in the antipsychotic literature: no other antipsychotic has demonstrated superiority over an active comparator on a primary negative symptom endpoint in a dedicated head-to-head trial. The result has been incorporated into multiple treatment guidelines and has positioned cariprazine as the preferred pharmacological option for negative-symptom-predominant schizophrenia.

7.4 Bipolar I disorder: manic or mixed episodes

Three Phase 3, randomized, double-blind, placebo-controlled trials established efficacy in bipolar I mania at doses of 3 to 12 mg/day [14]. Across trials, cariprazine demonstrated statistically significant improvement on the Young Mania Rating Scale (YMRS) total score versus placebo, with effect sizes (Cohen's d) of approximately 0.4 to 0.6. The approved dose range for bipolar mania is 3 to 6 mg/day, with a recommended starting dose of 1.5 mg/day on day 1 and titration to 3 mg/day on day 2.

7.5 Bipolar I disorder: depressive episodes

Three Phase 3, randomized, double-blind, placebo-controlled trials evaluated cariprazine in bipolar I depression [15, 16]. The pivotal study (RGH-MD-54) enrolled 488 patients randomized to placebo, cariprazine 1.5 mg/day, or cariprazine 3 mg/day for 6 weeks. Both cariprazine doses demonstrated statistically significant improvement on the MADRS total score versus placebo at week 6 (1.5 mg: LSM difference -2.5, $p = 0.0331$; 3 mg: LSM difference -3.0, $p = 0.0103$) [15]. A second positive study (RGH-MD-56) confirmed efficacy at 1.5 mg/day. The approved dose range for bipolar depression is 1.5 to 3 mg/day, with a recommended starting dose of 1.5 mg/day.

Post hoc analyses of the bipolar depression trials demonstrated that cariprazine improved anhedonia-related MADRS items (inability to feel, apparent sadness, lassitude) and functional outcomes (Sheehan Disability Scale), suggesting that the D3-preferring mechanism contributes to improvement in the hedonic and motivational dimensions of bipolar depression [31].

7.6 Major depressive disorder: adjunctive therapy

Two Phase 3, randomized, double-blind, placebo-controlled trials evaluated cariprazine as adjunctive therapy to ongoing antidepressant treatment in adults with MDD who had an inadequate response to 1 to 2 adequate antidepressant trials [17, 18]. In the positive trial (Study 3111-301-001), adjunctive cariprazine 1.5 mg/day demonstrated statistically significant improvement on MADRS total score versus placebo at week 6 (LSM difference approximately -2.2, $p = 0.005$). The 3 mg/day dose showed numerical improvement that did not reach statistical significance in this trial. A second trial produced mixed results, with the primary endpoint not consistently met, necessitating the totality of evidence assessment by FDA that ultimately supported approval [17, 18].

The FDA approved cariprazine for adjunctive treatment of MDD in December 2022 at a recommended dose of 1.5 mg/day, making cariprazine the fourth atypical antipsychotic approved for this indication (after aripiprazole, brexpiprazole, and quetiapine XR).

8. Sourcing and Quality Verification

Pharmaceutical-grade cariprazine (Vraylar brand) is the highest quality source for clinical and translational research applications. The marketed formulation is supplied as hard gelatin capsules containing cariprazine hydrochloride equivalent to 1.5 mg, 3 mg, 4.5 mg, and 6 mg of cariprazine free base. The product is widely available through standard pharmaceutical distribution channels in the United States and in European jurisdictions where Reagila is marketed [28].

Research-grade cariprazine is supplied by multiple chemical and pharmaceutical research suppliers (MedChemExpress, Selleckchem, Cayman Chemical, Tocris, Sigma-Aldrich, APExBIO, and others) at greater than 98 percent purity by HPLC. Supply is in milligram to gram quantities as the free base or as the hydrochloride salt. Pricing is moderate, typically in the range of \$100 to \$400 per 100 mg of research-grade material at the time of monograph preparation.

Research-grade DCAR and DDCAR are also commercially available from specialty suppliers (MedChemExpress, others) for in vitro pharmacology and metabolism studies.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (427.41 +/- 0.01 for the protonated free base [M+H]⁺)
- Nuclear magnetic resonance spectroscopy (1H and 13C) to confirm structural identity and diastereomeric configuration
- Karl Fischer or loss-on-drying analysis for residual water content
- Residual solvent analysis by gas chromatography

Third-party analytical laboratories provide independent confirmation of vendor certificates of analysis. The research-grade cariprazine market is established, and lot-to-lot variability is generally within acceptable limits. On-receipt analytical con-

firmation is appropriate for any investigation where dose-response precision is critical.

9. Reconstitution and Handling

Cariprazine hydrochloride is a crystalline solid with limited aqueous solubility at neutral pH. For in vitro research applications, the compound is typically prepared as a concentrated stock solution in dimethyl sulfoxide (DMSO) at 10 to 50 mM, stored in single-use aliquots at minus 20 degrees Celsius. DMSO stock solutions are stable for at least 6 months at minus 20 degrees Celsius when protected from light and moisture. Working dilutions for cell-based assays are prepared in culture medium immediately before use, with final DMSO concentrations maintained below 0.1 percent (v/v) to minimize vehicle effects on cellular function.

For in vivo preclinical research, cariprazine is formulated as a suspension in 0.5 percent methylcellulose or as a solution in acidified saline (pH 3 to 4) for oral gavage administration. Intraperitoneal and subcutaneous routes have been used in published rodent studies with formulation in saline with the addition of a small amount of acetic acid or tartaric acid to facilitate dissolution [25, 26].

The pharmaceutical-grade capsule formulation should be stored at controlled room temperature (20 to 25 degrees Celsius) and protected from moisture. No refrigeration is required for the marketed oral capsule.

For research applications requiring parenteral administration, cariprazine can be dissolved in a small volume of dimethylacetamide or N-methylpyrrolidone, then diluted into a biocompatible vehicle (PEG 400, polysorbate 80, or cyclodextrin solution). Investigators should confirm solubility and stability in their selected vehicle before initiating in vivo studies.

10. Stack Interactions and Combinations

Cariprazine interacts with several drug classes through its CYP3A4-dependent metabolism and through its dopaminergic and serotonergic pharmacology. Investigators and clinicians should consider the following interaction categories:

Strong CYP3A4 inhibitors: Ketoconazole, itraconazole, clarithromycin, and ritonavir substantially increase cariprazine and metabolite exposure. The prescribing label mandates dose reduction (maximum 1.5 mg daily or 3 mg every other day) during concomitant use. Investigators using cariprazine in combination pharmacology studies involving CYP3A4 inhibitors should anticipate elevated exposure and prolonged activity [28].

Strong CYP3A4 inducers: Carbamazepine, rifampin, phenytoin, phenobarbital, and St. John's wort reduce cariprazine exposure by increasing metabolic clearance. Concomitant use with strong CYP3A4 inducers is not recommended. This interaction is clinically significant because carbamazepine is commonly used as a mood stabilizer in bipolar disorder, the same population in which cariprazine is indicated [28].

Other antipsychotics: Concurrent use of two antipsychotics with D2 activity produces additive D2 receptor occupancy and increases the risk of extrapyramidal symptoms, akathisia, and neuroleptic malignant syndrome. The combination of cariprazine with a potent D2 antagonist (haloperidol, risperidone) is not recommended unless the clinical rationale is clearly defined.

Dopamine agonists: Concurrent administration with dopamine agonists used in Parkinson's disease (levodopa, pramipexole, ropinirole) produces pharmacological antagonism at the D2 receptor through cariprazine's partial agonist activity. The interaction may reduce the efficacy of both compounds. Use of cariprazine in patients receiving dopamine agonist therapy should be approached with caution.

CNS depressants: Concurrent use with benzodiazepines, opioids, alcohol, or sedating antihistamines may produce additive sedation. Cariprazine itself has low sedation liability (low H1 binding), but the combination should be monitored.

Serotonergic agents: Concurrent use with selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, triptans, or tramadol theoretically increases the risk of serotonin syndrome through the 5-HT_{1A} partial agonist activity. However, the clinical incidence of serotonin syndrome with cariprazine in combination with antidepressants is extremely low, as demonstrated in the MDD adjunctive trials where cariprazine was administered alongside ongoing antidepressant therapy without signal for serotonin syndrome [17, 18].

QT-prolonging agents: Cariprazine does not produce clinically significant QT prolongation at therapeutic doses in the thorough QT study. However, the combination with other antipsychotics or QT-prolonging medications warrants monitoring [28].

Lithium and valproate: Cariprazine can be used concomitantly with lithium or valproate in bipolar disorder without significant pharmacokinetic interaction. No dose adjustment is required for either compound [28].

11. Adverse Events and Safety

11.1 Common adverse events

The adverse-event profile of cariprazine has been characterized in pooled analyses across Phase 2 and Phase 3 trials in schizophrenia, bipolar mania, bipolar depression, and MDD [19, 28].

The most commonly reported treatment-emergent adverse events (incidence greater than 5 percent and at least twice the rate of placebo) across indications are:

- Akathisia (7 to 15 percent, dose-dependent; the most characteristic adverse event of cariprazine and the dopamine partial agonist class)
- Extrapyramidal symptoms (excluding akathisia; 5 to 15 percent, dose-dependent; includes parkinsonian symptoms, dystonia, and dyskinesia)
- Insomnia (8 to 14 percent)
- Headache (10 to 12 percent)
- Nausea (5 to 8 percent)
- Restlessness (4 to 7 percent)
- Tremor (3 to 6 percent)
- Constipation (3 to 6 percent)

The akathisia and extrapyramidal symptoms are dose-dependent and typically emerge in the first 2 to 4 weeks of treatment, though the long half-life of DDCAR means that adverse events may first appear several weeks after initiation, as plasma levels of total active moieties continue to accumulate toward steady state [19]. Most akathisia is mild (71 percent) or moderate (26.5 percent), and greater than 93 percent of patients with akathisia remained on treatment in pooled analyses.

11.2 Metabolic effects

The metabolic safety profile of cariprazine is comparatively favorable within the atypical antipsychotic class [19, 28]:

- Weight gain: mean weight increase of approximately 1 kg in short-term trials; approximately 1.6 kg in 48-week open-label extension studies. Clinically significant weight gain (7 percent or greater increase from baseline) was observed in 3 to 5 percent of cariprazine-treated patients versus 1 to 2 percent of placebo-treated patients in short-term trials.
- Fasting glucose: no clinically significant mean changes; the incidence of shifts from normal to high was similar between cariprazine and placebo.
- Lipid parameters: no clinically significant mean changes in total cholesterol, LDL cholesterol, or triglycerides.
- Metabolic syndrome: the overall metabolic profile is consistent with a metabolically neutral to mildly adverse agent, substantially more favorable than olanzapine, clozapine, and quetiapine, and comparable to aripiprazole and ziprasidone.

11.3 Prolactin effects

Cariprazine produces minimal prolactin elevation owing to its D2 partial agonist activity, which preserves dopaminergic tone in the tuberoinfundibular pathway. In some studies, cariprazine modestly reduced prolactin levels from baseline. This is a shared advantage with aripiprazole and brexpiprazole and a significant differentiator from risperidone, paliperidone, and haloperidol [19, 28].

11.4 Cardiovascular effects

Cariprazine does not produce clinically significant QT prolongation at therapeutic doses. Orthostatic hypotension is uncommon owing to the low alpha-1 adrenergic affinity. Tachycardia is infrequent. Blood pressure changes in long-term studies are generally not clinically significant [19, 28].

11.5 Boxed warnings and class effects

Cariprazine carries the standard antipsychotic class boxed warnings [28]:

- Increased mortality in elderly patients with dementia-related psychosis (cariprazine is not approved for this use)
- Suicidal thoughts and behaviors in children, adolescents, and young adults taking antidepressants (relevant to the MDD adjunctive indication)

Additional class-effect warnings include neuroleptic malignant syndrome (rare), tardive dyskinesia (incidence less than 1 percent in clinical trials), leukopenia and neutropenia, and metabolic changes.

11.6 Pregnancy and lactation

Cariprazine is not assigned a traditional FDA pregnancy letter category (the letter category system was replaced by narrative labeling in 2015). Third-trimester exposure to antipsychotics may cause extrapyramidal symptoms and withdrawal symptoms in neonates. Animal reproductive studies at multiples of the human dose showed no teratogenicity but did show reduced fetal viability. Use during pregnancy should be based on individual benefit-risk assessment. Data on excretion in human milk are limited; a decision should be made to discontinue nursing or to discontinue the drug [28].

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five alternative atypical antipsychotic agents against cariprazine, evaluated against five competency standards: novelty, effect size, promising potential (current clinical trajectory and breadth of indications), side-effect profile, and overall validation. The five comparators were selected to represent the principal pharmacological alternatives across the dopamine partial agonist class, the serotonin-dopamine antagonist class, and emerging mechanisms.

12.1 Aripiprazole (Abilify)

Mechanism: Dopamine D2/D3 partial agonist and serotonin 5-HT1A partial agonist. Aripiprazole has the highest intrinsic activity at D2 among the partial agonist antipsychotics (approximately 25 to 30 percent of dopamine maximum) and lower D3 selectivity than cariprazine (D3 Ki approximately 0.8 nM versus cariprazine D3 Ki approximately 0.085 nM) [5, 6, 32].

Novelty: Low. Aripiprazole was the first dopamine partial agonist antipsychotic approved (2002) and is now a well-established generic medication. It pioneered the partial agonist concept but does not have the D3-preferring profile of cariprazine.

Effect size: Moderate. Aripiprazole has demonstrated efficacy across schizophrenia, bipolar mania, bipolar depression (as adjunctive therapy), MDD (as adjunctive therapy), irritability in autism, and Tourette syndrome. Effect sizes in schizophrenia trials are broadly comparable to cariprazine. Aripiprazole has not demonstrated superiority over an active comparator on negative symptoms in a dedicated trial.

Promising potential: Moderate to high. The compound has the broadest approved indication set of any atypical antipsychotic and is available in oral, intramuscular acute, and long-acting injectable formulations. Generic availability has reduced cost.

Side-effect profile: Similar to cariprazine in the akathisia, insomnia, and extrapyramidal symptom domains. Metabolic profile is favorable (comparable to cariprazine). Aripiprazole has a higher rate of activation-type adverse events (insomnia, agitation) than cariprazine in some comparative analyses, likely attributable to the higher D2 intrinsic activity [5, 6].

Overall validation: High. Aripiprazole has the largest clinical evidence base of any dopamine partial agonist and extensive real-world prescribing data spanning over 20 years.

Comparison to cariprazine: Cariprazine offers higher D3 selectivity, demonstrated superiority over risperidone on negative symptoms, and a potentially more favorable activation side-effect profile. Aripiprazole offers broader indication coverage, generic pricing, and long-acting injectable formulations.

12.2 Brexpiprazole (Rexulti)

Mechanism: Dopamine D2 partial agonist (lower intrinsic activity than aripiprazole), serotonin 5-HT1A partial agonist, and serotonin 5-HT2A antagonist. Brexpiprazole has moderate D3 affinity but lower D3 selectivity than cariprazine [5, 6, 33].

Novelty: Low to moderate. Brexpiprazole was designed to improve on aripiprazole's tolerability by reducing D2 intrinsic activity and adding stronger 5-HT2A antagonism and alpha-1B adrenergic antagonism to reduce akathisia and activation.

Effect size: Moderate. Approved for schizophrenia and adjunctive treatment of MDD. In schizophrenia trials, effect sizes are similar to cariprazine and aripiprazole. In MDD adjunctive trials, brexpiprazole has demonstrated consistent efficacy. Brexpiprazole was recently approved for agitation associated with Alzheimer's dementia, a unique indication. Brexpiprazole has not been studied or approved for bipolar disorder.

Promising potential: Moderate. The Alzheimer's agitation approval is a differentiating indication. The compound does not have bipolar disorder indications.

Side-effect profile: Brexpiprazole produces less akathisia than cariprazine and aripiprazole, consistent with its lower D2 intrinsic activity and stronger 5-HT2A antagonism. However, brexpiprazole produces more weight gain than cariprazine

(mean weight increase approximately 1.3 to 2.2 kg in short-term trials) and more sedation than cariprazine (attributable to 5-HT_{2A} antagonism and alpha-1 adrenergic antagonism) [5, 6, 33].

Overall validation: Moderate to high. Robust clinical trial evidence for schizophrenia and MDD adjunctive therapy, and the novel Alzheimer's agitation indication.

Comparison to cariprazine: Cariprazine offers higher D₃ selectivity, negative symptom superiority data, and bipolar disorder indications. Brexpiprazole offers lower akathisia rates, the Alzheimer's agitation indication, and potentially better tolerability in patients sensitive to activation-type side effects.

12.3 Lumateperone (Caplyta)

Mechanism: Serotonin 5-HT_{2A} antagonist, dopamine D₂ receptor partial agonist (at presynaptic receptors) and postsynaptic antagonist, serotonin reuptake inhibitor, and glutamate GluN_{2B} modulator. Lumateperone has a fundamentally different mechanism from cariprazine, with minimal D₃ activity [34].

Novelty: High. Lumateperone combines serotonin, dopamine, and glutamate modulation in a single molecule at its therapeutic dose (42 mg), an approach not shared by any other marketed antipsychotic.

Effect size: Moderate. Approved for schizophrenia, bipolar depression (monotherapy and adjunctive to lithium or valproate), and adjunctive treatment of MDD. In bipolar depression, lumateperone 42 mg demonstrated efficacy both as monotherapy and as adjunctive therapy, with effect sizes comparable to cariprazine. In some network meta-analyses, lumateperone showed strong results among adjunctive antipsychotics for MDD [34].

Promising potential: High. The triple-mechanism approach and the tolerability profile position lumateperone as an emerging alternative across mood and psychotic disorders.

Side-effect profile: Lumateperone has the most favorable metabolic and movement-disorder profile among the evaluated comparators. Weight gain is minimal (less than 1 kg on average). Akathisia and extrapyramidal symptoms are comparable to placebo. The principal adverse events are somnolence and sedation, consistent with the 5-HT_{2A} antagonism. Prolactin elevation is not significant [34].

Overall validation: Moderate. The compound is newer (FDA approval 2019 for schizophrenia) with a growing evidence base. Long-term safety data are less extensive than for aripiprazole or cariprazine.

Comparison to cariprazine: Cariprazine offers the D3-preferring profile with negative symptom superiority data and bipolar mania indication. Lumateperone offers a substantially more favorable movement-disorder and metabolic profile with the glutamate modulation mechanism as a differentiator. Lumateperone does not have a bipolar mania indication.

12.4 Risperidone (Risperdal)

Mechanism: Serotonin 5-HT_{2A} antagonist and dopamine D₂ antagonist. Risperidone is the prototypical serotonin-dopamine antagonist (SDA) antipsychotic, with potent D₂ antagonism (not partial agonism) and potent 5-HT_{2A} antagonism. D₃ affinity is moderate but is overwhelmed by D₂ antagonism at clinical doses [35].

Novelty: Low. Risperidone was the second atypical antipsychotic approved (1993) and is now a well-established generic medication.

Effect size: High for positive symptoms. Risperidone is among the most effective antipsychotics for positive symptoms of schizophrenia in network meta-analyses. However, risperidone was inferior to cariprazine on negative symptoms in the Nemeth et al. (2017) head-to-head trial [13]. Risperidone has limited efficacy for negative symptoms, cognitive impairment, and depressive symptoms.

Promising potential: Low to moderate. The compound is well established but faces competition from newer agents with better tolerability profiles. Available in oral and long-acting injectable formulations.

Side-effect profile: Risperidone produces substantial prolactin elevation (the highest among commonly used atypical antipsychotics), moderate weight gain (approximately 2 to 3 kg in short-term trials), dose-dependent extrapyramidal symptoms, and orthostatic hypotension. The metabolic profile is intermediate [35].

Overall validation: Very high. Risperidone has the longest clinical track record among second-generation antipsychotics (after clozapine) and the largest evidence base for schizophrenia.

Comparison to cariprazine: Cariprazine offers D3-preferring pharmacology with demonstrated superiority on negative symptoms, substantially lower prolactin elevation, and a more favorable metabolic profile. Risperidone offers potentially greater efficacy on positive symptoms, long-acting injectable formulations, and lower cost as a generic medication.

12.5 Olanzapine (Zyprexa)

Mechanism: Multi-receptor antagonist with high affinity for serotonin 5-HT_{2A}, dopamine D₂, histamine H₁, muscarinic M₁ to M₅, and alpha-1 adrenergic receptors. Olanzapine has low D₃ selectivity and no partial agonist activity at dopamine receptors [36].

Novelty: Low. Olanzapine was approved in 1996 and is a well-established generic medication.

Effect size: High for overall symptom reduction. Olanzapine is consistently ranked among the most effective antipsychotics in network meta-analyses. The olanzapine/fluoxetine combination (Symbyax) is approved for bipolar depression and treatment-resistant depression. However, olanzapine does not have specific efficacy data for negative symptoms comparable to cariprazine.

Promising potential: Low. The compound is well established with a declining market position due to metabolic safety concerns.

Side-effect profile: Olanzapine has the most unfavorable metabolic profile among commonly used atypical antipsychotics. Mean weight gain in short-term trials is approximately 3 to 5 kg, with long-term weight gain of 7 to 10 kg in many patients. Clinically significant increases in fasting glucose, triglycerides, and total cholesterol are common. The compound produces significant sedation (H₁ antagonism), moderate anticholinergic effects (muscarinic antagonism), and low extrapyramidal symptoms [36].

Overall validation: Very high. Olanzapine has one of the largest clinical evidence bases in psychiatry and is a standard comparator in clinical trials.

Comparison to cariprazine: Cariprazine offers a dramatically more favorable metabolic profile, lower sedation, and demonstrated D₃-mediated negative symptom efficacy. Olanzapine offers potentially greater overall antipsychotic efficacy

(particularly in treatment-resistant patients when combined with clozapine), more sedation (which may be clinically useful in acutely agitated patients), and the bipolar depression approval as the olanzapine/fluoxetine combination.

12.6 Comparator summary

The five comparators occupy distinct positions in the atypical antipsychotic landscape. **Aripiprazole** is the most closely related pharmacological agent (dopamine partial agonist class) but lacks cariprazine's D3 preferential binding and negative symptom superiority data. **Brexpiprazole** offers improved tolerability (lower akathisia) at the cost of higher weight gain and narrower indication coverage. **Lumateperone** represents the most mechanistically novel comparator with the most favorable tolerability profile, but lacks the D3-mediated negative symptom mechanism and the bipolar mania indication. **Risperidone** serves as the active comparator against which cariprazine's negative symptom superiority was demonstrated, and retains a position for positive symptom efficacy and as a long-acting injectable. **Olanzapine** offers high overall efficacy but at the cost of the most unfavorable metabolic safety profile in the class.

Cariprazine occupies a unique position: it is the only marketed antipsychotic with demonstrated head-to-head superiority over an active comparator on negative symptoms of schizophrenia, the only D3-preferring agent in clinical use, and one of a small number of atypical antipsychotics approved across schizophrenia, bipolar mania, bipolar depression, and adjunctive MDD. Its principal limitation is the akathisia and extrapyramidal symptom liability, which is dose-dependent and manageable but which distinguishes it unfavorably from lumateperone and brexpiprazole in patients who are sensitive to movement-disorder adverse events. The long functional half-life (driven by DDCA) is both an advantage (sustained efficacy, forgiving of missed doses) and a disadvantage (slow titration, prolonged washout, delayed adverse-event recognition).

Investigators considering cariprazine for translational or clinical research should expect moderate effect sizes on positive symptoms consistent with the atypical antipsychotic class, with the D3-preferring mechanism conferring a differentiated advantage on negative symptoms, cognition, and motivational/hedonic constructs. The comparator landscape (aripiprazole as generic first-line partial agonist, brexpiprazole for tolerability-sensitive patients, lumateperone for metabolic safety,

risperidone for positive symptom potency, olanzapine for overall efficacy) provides the context for positioning cariprazine within a treatment algorithm and for designing comparative research.

13. References

1. Kiss B, Horvath A, Nemethy Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. *J Pharmacol Exp Ther*. 2010;333(1):328-340.
2. Kiss B, Horvath A, Nemethy Z, et al. Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays unique receptor occupancy profile. *Eur Neuropsychopharmacol*. 2008;18(Suppl 4):S493.
3. Agai-Csongor E, Domany G, Nogradi K, et al. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. *Bioorg Med Chem Lett*. 2012;22(10):3437-3440.
4. Gedeon Richter Plc. Cariprazine: from discovery to global therapy. Corporate communications. 2025.
5. Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. *Ther Adv Psychopharmacol*. 2017;7(1):29-41.
6. Stahl SM. Mechanism of action of cariprazine. *CNS Spectr*. 2016;21(2):123-127.
7. Gyertyan I, Kiss B, Saghy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. *Neurochem Int*. 2011;59(6):925-935.
8. Nakamura T, Kubota T, Iwakaji A, et al. Population pharmacokinetics of cariprazine and its major metabolites. *Eur J Drug Metab Pharmacokinet*. 2021;46(1):55-69.
9. Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a Phase II, randomized clinical trial. *Schizophr Res*. 2014;152(2-3):450-457.
10. Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, Phase III clinical trial. *J Clin Psychopharmacol*. 2015;35(4):367-373.

11. Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, Phase 3, randomized, double-blind, placebo- and active-controlled trial. *J Clin Psychiatry*. 2015;76(12):e1574-e1582.
12. Durgam S, Earley W, Li R, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. *Schizophr Res*. 2016;176(2-3):264-271.
13. Nemeth G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. *Lancet*. 2017;389(10074):1103-1113.
14. Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a Phase II trial. *Bipolar Disord*. 2015;17(1):63-75.
15. Earley W, Burgess MV, Rekedal L, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled Phase 3 study. *Am J Psychiatry*. 2019;176(6):439-448.
16. Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. *J Clin Psychiatry*. 2016;77(3):371-378.
17. Vieta E, Earley W, Engel M, et al. Adjunctive cariprazine for the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled Phase 3 study. *Am J Psychiatry*. 2023;180(3):241-250.
18. Fava M, Durgam S, Earley W, et al. Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2018;79(5):17m11834.
19. Nasrallah HA, Earley W, Engel M, et al. Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight Phase II/III studies. *Neuropsychiatr Dis Treat*. 2021;17:2455-2468.
20. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. *Nature*. 1990;347(6289):146-151.

21. US Food and Drug Administration. Approval letter: Vraylar (cariprazine) capsules. NDA 204370. September 17, 2015.
22. US Food and Drug Administration. Approval letter: Vraylar (cariprazine) capsules supplemental NDA for bipolar depression. May 28, 2019.
23. US Food and Drug Administration. Approval letter: Vraylar (cariprazine) capsules supplemental NDA for adjunctive MDD. December 16, 2022.
24. Girgis RR, Slifstein M, D'Souza D, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3-preferring ligand [11C]-(+)-PHNO. *Psychopharmacology (Berl)*. 2016;233(19-20):3503-3512.
25. Gyertyan I, Kiss B, Saghy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. *Neurochem Int*. 2011;59(6):925-935.
26. Zimnisky R, Chang G, Gyertyan I, et al. Cariprazine, a dopamine D3-receptor-preferring partial agonist, attenuates drug-induced deficits in cognition and social interaction in rats. *Psychopharmacology (Berl)*. 2013;226(1):193-203.
27. Stahl SM. Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data. *Ther Adv Psychopharmacol*. 2020;10:2045125320905752.
28. AbbVie Inc. Vraylar (cariprazine) capsules prescribing information. US Food and Drug Administration. Revised 2024.
29. Nakamura T, Kubota T, Iwakaji A, et al. Population pharmacokinetics of cariprazine and its major metabolites. *Eur J Drug Metab Pharmacokinet*. 2021;46(1):55-69.
30. Fleischhacker W, Galderisi S, Laszlovszky I, et al. The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors. *Eur Psychiatry*. 2019;58:1-9.
31. Earley WR, Burgess MV, Khan B, et al. Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled Phase 3 study. *Bipolar Disord*. 2020;22(4):372-384.

32. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. *Neuropsychopharmacology*. 2003;28(8):1400-1411.
33. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. *J Pharmacol Exp Ther*. 2014;350(3):589-604.
34. Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a Phase 3 randomized placebo-controlled trial. *Am J Psychiatry*. 2021;178(12):1098-1106.
35. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet*. 2013;382(9896):951-962.
36. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. *CNS Drugs*. 2013;27(11):879-911.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Cariprazine is approved by the United States Food and Drug Administration for the treatment of schizophrenia, bipolar I mania, bipolar I depression, and adjunctive treatment of major depressive disorder. Investigators should consult their local regulatory authority and the current prescribing information before any clinical or research application.